首页> 外文期刊>Metal-based drugs >Regulation of Cisplatin Cytotoxicity by Cu Influx Transporters
【24h】

Regulation of Cisplatin Cytotoxicity by Cu Influx Transporters

机译:铜流入转运蛋白对顺铂细胞毒性的调节

获取原文
获取原文并翻译 | 示例
           

摘要

Platinum drugs are an important class of cancer chemotherapeutics. However, the use of these drugs is limited by the development of resistance during treatment with decreased accumulation being a common mechanism. Both Cu transporters CTR1 and CTR2 influence the uptake and cytotoxicity of cisplatin. Although it is structurally similar to CTR1, CTR2 functions in a manner opposite to that of CTR1 with respect to Pt drug uptake. Whereas knockout of CTR1 reduces Pt drug uptake, knockdown of CTR2 enhances cisplatin uptake and cytotoxicity. CTR2 is subject to transcriptional and posttranscriptional regulation by both Cu and cisplatin; this regulation is partly dependent on the Cu chaperone ATOX1. Insight into the mechanisms by which CTR1 and CTR2 regulate sensitivity to the Pt-containing drugs has served as the basis for novel pharmacologic strategies for improving their efficacy.
机译:铂类药物是癌症化学治疗的重要一类。然而,这些药物的使用受到治疗过程中耐药性的发展的限制,其中累积的减少是常见的机制。 Cu转运蛋白CTR1和CTR2都影响顺铂的摄取和细胞毒性。尽管在结构上与CTR1类似,但CTR2在吸收Pt方面的功能与CTR1相反。敲除CTR1会降低Pt药物的吸收,而敲除CTR2会增加顺铂的吸收和细胞毒性。 CTR2受到铜和顺铂的转录和转录后调控;该法规部分取决于铜分子伴侣ATOX1。对CTR1和CTR2调节对含Pt药物的敏感性的机制的深入了解已成为改善其功效的新药理学策略的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号